VCFS
MCID: VLC001
MIFTS: 62

Velocardiofacial Syndrome (VCFS) malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Cardiovascular diseases, Nephrological diseases, Ear diseases, Endocrine diseases, Fetal diseases, Blood diseases

Aliases & Classifications for Velocardiofacial Syndrome

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 23GeneReviews, 24GeneTests, 25Genetics Home Reference, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 37MedGen, 39MeSH, 40MESH via Orphanet, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot, 71Wikipedia
See all MalaCards sources

Aliases & Descriptions for Velocardiofacial Syndrome:

Name: Velocardiofacial Syndrome 52 11 48 24 25 54 70 12 50 13
Shprintzen Syndrome 11 48 24 25 54 27 68
22q11.2 Deletion Syndrome 71 23 48 24 25 54
Conotruncal Anomaly Face Syndrome 48 25 54 68
Sedlackova Syndrome 48 24 25 54
Digeorge Syndrome 48 25 54 68
Vcfs 48 24 25 70
Cayler Cardiofacial Syndrome 48 25 54
Velo-Cardio-Facial Syndrome 25 70 50
Deletion 22q11.2 Syndrome 11 24 25
22q11.2ds 23 24 25
Catch22 48 24 25
Autosomal Dominant Opitz G/bbb Syndrome 48 25
 
Chromosome 22q11.2 Deletion Syndrome 48 70
22q11 Deletion Syndrome 11 68
Vcf-Velocardiofacial Syndrome 11
Caylor Cardiofacial Syndrome 71
Shprintzen Vcf Syndrome 70
Microdeletion 22q11.2 54
Digeorge Sequence 54
Takao Syndrome 54
Monosomy 22q11 54
Vcf Syndrome 70
Del 22q11.2 24
Catch 22 54
22q11ds 54

Characteristics:

Orphanet epidemiological data:

54
velocardiofacial syndrome:
Inheritance: Autosomal dominant,Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: Neonatal; Age of death: any age

HPO:

64
velocardiofacial syndrome:
Inheritance: autosomal dominant inheritance

GeneReviews:

23
Penetrance: penetrance is complete in individuals with 22q112ds; variability is marked...


Classifications:



External Ids:

OMIM52 192430
Disease Ontology11 DOID:12583
ICD1030 Q93.81
ICD9CM32 758.32
MeSH39 D004062
SNOMED-CT62 205642004, 83092002
Orphanet54 ORPHA567
UMLS via Orphanet69 C0012236, C0220704, C0795907 C2936346, C3266101, more
ICD10 via Orphanet31 D82.1
MESH via Orphanet40 D058165
MedGen37 C0220704

Summaries for Velocardiofacial Syndrome

About this section
NIH Rare Diseases:48 22q11.2 deletion syndrome is a disorder that involves many different areas of the body and can vary greatly in severity among people with the condition. signs and symptoms may include: cleft palate, heart defects, recurrent infections, unique facial characteristics, feeding problems, kidney abnormalities, hypoparathyroidism, thrombocytopenia, scoliosis, hearing loss, developmental delay, and learning disabilities. people with this condition are also more likely to develop certain autoimmune disorders and personality disorders. 22q11.2 deletion syndrome is caused by a deletion of a small part of chromosome 22 near the middle of the chromosome at a location known as q11.2. in most cases, the syndrome occurs for the first time in the affected person; about 10% of cases are inherited from a parent. it is inherited in an autosomal dominant manner. although there is no specific treatment or cure, there can be ways to manage the symptoms. a team of doctors is often needed to figure out the treatment options based on each person’s symptoms. last updated: 5/1/2017

MalaCards based summary: Velocardiofacial Syndrome, also known as shprintzen syndrome, is related to cayler cardiofacial syndrome and chromosome 22q11.2 deletion syndrome, distal, and has symptoms including Array, Array and Array. An important gene associated with Velocardiofacial Syndrome is TBX1 (T-Box 1), and among its related pathways are ECM-receptor interaction and Formation of Fibrin Clot (Clotting Cascade). Affiliated tissues include heart, thymus and kidney.

Disease Ontology:11 A chromosomal disease that has material basis in deletion polymorphisms at chromosome location 22q11 and is characterized by variable developmental problems and schizoid features.

Genetics Home Reference:25 22q11.2 deletion syndrome (which is also known by several other names, listed below) is a disorder caused by the deletion of a small piece of chromosome 22. The deletion occurs near the middle of the chromosome at a location designated q11.2.

UniProtKB/Swiss-Prot:70 Velocardiofacial syndrome: A syndrome characterized by abnormal pharyngeal arch development that results in defective development of the parathyroid glands, thymus, and conotruncal region of the heart. The phenotype is highly variable, with no single clinical feature present in every patient. Affected individuals may present with structural or functional palatal abnormalities, cardiac defects, unique facial characteristics, hypernasal speech, hypotonia, and defective thymic development associated with impaired immune function. In addition, affected individuals may present with learning disabilities, overt developmental delay, and psychiatric disorders.

Description from OMIM:52 192430

GeneReviews for NBK1523

Related Diseases for Velocardiofacial Syndrome

About this section

Diseases in the Velocardiofacial Syndrome family:

Velocardiofacial Syndrome 2

Diseases related to Velocardiofacial Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 61)
idRelated DiseaseScoreTop Affiliating Genes
1cayler cardiofacial syndrome12.5
2chromosome 22q11.2 deletion syndrome, distal12.1
3digeorge syndrome/velocardiofacial syndrome complex 211.9
4velocardiofacial syndrome 211.8
5goldberg-shprintzen megacolon syndrome11.7
6conotruncal heart malformations11.5
7opitz gbbb syndrome, type ii11.5
8opitz-gbbb syndrome11.5
9digeorge syndrome11.3
10mrpl40-related disorder10.8
11digeorge syndrome 210.8
12essential thrombocythemia10.3GP1BA, GP1BB, GP9
13immunodeficiency 2110.3GP1BA, GP1BB, GP9
14ocular hyperemia10.3GP1BA, GP1BB, GP9
15hypertrophic olivary degeneration10.2COMT, PRODH
16chondrodysplasia lethal recessive10.2COMT, PRODH
17myeloproliferative neoplasm10.2GP1BA, GP1BB, GP9
18fetal macrosomia10.2GP1BA, GP1BB
19chromosome 16p11.2 deletion syndrome, 220kb10.2COMT, GSC2, HIRA, PRODH, TBX1
20situs inversus10.1
21tracheal disease10.1GP1BA, GP1BB, GP9
22ceroid lipofuscinosis, neuronal, 810.1DGCR, HIRA, TBX1, UFD1
23pharyngitis10.0
24kenny-caffey syndrome10.0
25schizophrenia9.9
26attention deficit-hyperactivity disorder9.9
27autism spectrum disorder9.9
28hypoparathyroidism9.8
29beta-ureidopropionase deficiency9.8DGCR, DGCR14, DGCR2, DGCR6, GSC2, HIRA
30shprintzen-goldberg syndrome9.8
31arthritis9.8
32heart disease9.8
33cervicitis9.8
34omphalocele9.8
35oculo-auriculo-vertebral spectrum9.8
36tetralogy of fallot9.7
37craniosynostosis9.7
38polymicrogyria9.7
39rheumatoid arthritis9.6
40fragile x syndrome9.6
41chronic granulomatous disease9.6
42leukemia9.6
43tooth agenesis9.6
44distal arthrogryposis9.6
45apraxia9.6
46specific language impairment9.6
47portal hypertension9.6
48dementia9.6
49uveitis9.6
50down syndrome9.6

Graphical network of the top 20 diseases related to Velocardiofacial Syndrome:



Diseases related to velocardiofacial syndrome

Symptoms & Phenotypes for Velocardiofacial Syndrome

About this section

Symptoms by clinical synopsis from OMIM:

192430

Clinical features from OMIM:

192430

Human phenotypes related to Velocardiofacial Syndrome:

 54 64 (show all 152)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 vesicoureteral reflux64 54 Occasional (29-5%) HP:0000076
2 polycystic kidney dysplasia64 54 Occasional (29-5%) HP:0000113
3 abnormality of the uterus64 54 Occasional (29-5%) HP:0000130
4 narrow mouth64 54 Occasional (29-5%) HP:0000160
5 hydrocephalus64 54 Occasional (29-5%) HP:0000238
6 microcephaly64 54 Occasional (29-5%) HP:0000252
7 malar flattening64 54 Frequent (79-30%) HP:0000272
8 epicanthus64 54 Very frequent (99-80%) HP:0000286
9 long philtrum64 54 Frequent (79-30%) HP:0000343
10 micrognathia64 54 Occasional (29-5%) HP:0000347
11 low-set ears64 54 Very frequent (99-80%) HP:0000369
12 small earlobe64 54 Frequent (79-30%) HP:0000385
13 overfolded helix64 54 Frequent (79-30%) HP:0000396
14 prominent nasal bridge64 54 Very frequent (99-80%) HP:0000426
15 wide nasal bridge64 54 Very frequent (99-80%) HP:0000431
16 short neck64 54 Frequent (79-30%) HP:0000470
17 strabismus64 54 Occasional (29-5%) HP:0000486
18 downslanted palpebral fissures64 54 Occasional (29-5%) HP:0000494
19 ptosis64 54 Frequent (79-30%) HP:0000508
20 cataract64 54 Occasional (29-5%) HP:0000518
21 microphthalmia64 54 Occasional (29-5%) HP:0000568
22 upslanted palpebral fissure64 54 Very frequent (99-80%) HP:0000582
23 posterior embryotoxon64 54 Frequent (79-30%) HP:0000627
24 abnormality of dental enamel64 54 Occasional (29-5%) HP:0000682
25 behavioral abnormality54 Occasional (29-5%)
26 autism64 54 Occasional (29-5%) HP:0000717
27 anxiety64 54 Occasional (29-5%) HP:0000739
28 hypoplasia of the thymus64 54 Very frequent (99-80%) HP:0000778
29 abnormality of the skull54 Frequent (79-30%)
30 hypopigmented skin patches64 54 Occasional (29-5%) HP:0001053
31 retinal arteriolar tortuosity64 54 Occasional (29-5%) HP:0001136
32 seizures64 54 Occasional (29-5%) HP:0001250
33 tetany64 54 Frequent (79-30%) HP:0001281
34 polyhydramnios64 54 Occasional (29-5%) HP:0001561
35 atria septal defect54 Very frequent (99-80%)
36 tetralogy of fallot64 54 Very frequent (99-80%) HP:0001636
37 abnormality of the pulmonary valve64 54 Very frequent (99-80%) HP:0001641
38 patent ductus arteriosus64 54 Occasional (29-5%) HP:0001643
39 abnormality of the aortic valve64 54 Occasional (29-5%) HP:0001646
40 inguinal hernia64 54 Occasional (29-5%) HP:0000023
41 cryptorchidism64 54 Occasional (29-5%) HP:0000028
42 hypospadias64 54 Occasional (29-5%) HP:0000047
43 renal hypoplasia64 54 Frequent (79-30%) HP:0000089
44 abnormality of the teeth54 Frequent (79-30%)
45 cleft palate64 54 Very frequent (99-80%) HP:0000175
46 turricephaly64 54 Occasional (29-5%) HP:0000262
47 long face64 54 Frequent (79-30%) HP:0000276
48 hypertelorism64 54 Occasional (29-5%) HP:0000316
49 short philtrum64 54 Occasional (29-5%) HP:0000322
50 hearing impairment54 Frequent (79-30%)
51 chronic otitis media64 54 Frequent (79-30%) HP:0000389
52 conductive hearing impairment64 54 Very frequent (99-80%) HP:0000405
53 bulbous nose64 54 Very frequent (99-80%) HP:0000414
54 choanal atresia64 54 Occasional (29-5%) HP:0000453
55 abnormality of the eyelid54 Frequent (79-30%)
56 glaucoma64 54 Occasional (29-5%) HP:0000501
57 telecanthus64 54 Very frequent (99-80%) HP:0000506
58 abnormality of the pharynx64 54 Very frequent (99-80%) HP:0000600
59 optic atrophy64 54 Occasional (29-5%) HP:0000648
60 carious teeth64 54 Frequent (79-30%) HP:0000670
61 depression54 Occasional (29-5%)
62 abnormality of the thorax64 54 Occasional (29-5%) HP:0000765
63 hypothyroidism64 54 Occasional (29-5%) HP:0000821
64 hypoparathyroidism64 54 Frequent (79-30%) HP:0000829
65 hyperthyroidism64 54 Occasional (29-5%) HP:0000836
66 purpura64 54 Occasional (29-5%) HP:0000979
67 seborrheic dermatitis64 54 Frequent (79-30%) HP:0001051
68 acne64 54 Frequent (79-30%) HP:0001061
69 cholelithiasis64 54 Occasional (29-5%) HP:0001081
70 hand polydactyly64 54 Occasional (29-5%) HP:0001161
71 arachnodactyly64 54 Frequent (79-30%) HP:0001166
72 intellectual disability64 54 Occasional (29-5%) HP:0001249
73 muscular hypotonia64 54 Very frequent (99-80%) HP:0001252
74 intellectual disability, mild64 54 Frequent (79-30%) HP:0001256
75 global developmental delay64 54 Frequent (79-30%) HP:0001263
76 specific learning disability64 54 Frequent (79-30%) HP:0001328
77 arthritis64 54 Occasional (29-5%) HP:0001369
78 failure to thrive64 54 Occasional (29-5%) HP:0001508
79 intrauterine growth retardation64 54 Occasional (29-5%) HP:0001511
80 obesity64 54 Occasional (29-5%) HP:0001513
81 umbilical hernia64 54 Occasional (29-5%) HP:0001537
82 laryngomalacia64 54 Occasional (29-5%) HP:0001601
83 nasal speech64 54 Very frequent (99-80%) HP:0001611
84 ventricular septal defect64 54 Very frequent (99-80%) HP:0001629
85 truncus arteriosus64 54 Very frequent (99-80%) HP:0001660
86 splenomegaly64 54 Occasional (29-5%) HP:0001744
87 talipes equinovarus64 54 Occasional (29-5%) HP:0001762
88 foot polydactyly64 54 Occasional (29-5%) HP:0001829
89 abnormality of thrombocytes54 Occasional (29-5%)
90 thrombocytopenia64 54 Occasional (29-5%) HP:0001873
91 abnormal facial shape54 Very frequent (99-80%)
92 constipation64 54 Frequent (79-30%) HP:0002019
93 gastroesophageal reflux64 54 Occasional (29-5%) HP:0002020
94 anal atresia64 54 Occasional (29-5%) HP:0002023
95 asthma64 54 Occasional (29-5%) HP:0002099
96 arrhinencephaly64 54 Occasional (29-5%) HP:0002139
97 gastrointestinal hemorrhage64 54 Occasional (29-5%) HP:0002239
98 aganglionic megacolon64 54 Occasional (29-5%) HP:0002251
99 dysphasia64 54 Very frequent (99-80%) HP:0002357
100 spina bifida54 Occasional (29-5%)
101 meningocele54 Frequent (79-30%)
102 malformation of the heart and great vessels54 Very frequent (99-80%)
103 intestinal malrotation64 54 Occasional (29-5%) HP:0002566
104 bowel incontinence64 54 Occasional (29-5%) HP:0002607
105 varicose veins64 54 Occasional (29-5%) HP:0002619
106 scoliosis64 54 Occasional (29-5%) HP:0002650
107 platybasia64 54 Very frequent (99-80%) HP:0002691
108 immunodeficiency64 54 Very frequent (99-80%) HP:0002721
109 hypocalcemia64 54 Frequent (79-30%) HP:0002901
110 autoimmunity64 54 Occasional (29-5%) HP:0002960
111 patellar dislocation64 54 Occasional (29-5%) HP:0002999
112 myalgia64 54 Frequent (79-30%) HP:0003326
113 short stature64 54 Frequent (79-30%) HP:0004322
114 impaired t cell function64 54 Frequent (79-30%) HP:0005435
115 multiple renal cysts64 54 Occasional (29-5%) HP:0005562
116 joint hyperflexibility64 54 Occasional (29-5%) HP:0005692
117 chronic obstructive pulmonary disease64 54 Occasional (29-5%) HP:0006510
118 lung segmentation defects54 Occasional (29-5%)
119 attention deficit hyperactivity disorder64 54 Frequent (79-30%) HP:0007018
120 occipital myelomeningocele64 54 Frequent (79-30%) HP:0007271
121 bipolar affective disorder64 54 Occasional (29-5%) HP:0007302
122 feeding difficulties in infancy64 54 Occasional (29-5%) HP:0008872
123 multiple suture craniosynostosis64 54 Occasional (29-5%) HP:0011324
124 corneal neovascularization64 54 Frequent (79-30%) HP:0011496
125 tricuspid atresia64 54 Occasional (29-5%) HP:0011662
126 abnormality of the aortic arch64 54 Very frequent (99-80%) HP:0012303
127 anorectal anomaly54 Frequent (79-30%)
128 hypertensive crisis64 54 Occasional (29-5%) HP:0100735
129 atelectasis64 54 Occasional (29-5%) HP:0100750
130 schizophrenia64 54 Occasional (29-5%) HP:0100753
131 abnormality of the tonsils64 54 Frequent (79-30%) HP:0100765
132 delayed speech and language development64 HP:0000750
133 abnormal heart morphology64 HP:0001627
134 decrease in t cell count64 HP:0005403
135 open mouth64 HP:0000194
136 pierre-robin sequence64 HP:0000201
137 velopharyngeal insufficiency64 HP:0000220
138 retrognathia64 HP:0000278
139 underdeveloped nasal alae64 HP:0000430
140 blepharophimosis64 HP:0000581
141 abnormality of the ear64 HP:0000598
142 aggressive behavior64 HP:0000718
143 mood swings64 HP:0000720
144 abnormality of the endocrine system64 HP:0000818
145 abnormality of the hand64 HP:0001155
146 right aortic arch with mirror image branching64 HP:0002627
147 recurrent infections64 HP:0002719
148 unilateral primary pulmonary dysgenesis64 HP:0006549
149 paranoia64 HP:0011999
150 retinal vascular tortuosity64 HP:0012841
151 atrial septal defect64 HP:0001631
152 abnormal lung lobation64 HP:0002101

Drugs & Therapeutics for Velocardiofacial Syndrome

About this section

Drugs for Velocardiofacial Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 84)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DopamineapprovedPhase 4383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
2
Methylphenidateapproved, investigationalPhase 4375113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
 
Methyl phenidyl acetate
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
3
Risperidoneapproved, investigationalPhase 4492106266-06-25073
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
BIDD:GT0262
BRD-K53857191-001-04-5
BRN 4891881
Belivon
Bio-0092
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
CPD000466323
Consta, Risperdal
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
LS-134196
Lopac-R-118
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
 
NCGC00015883-01
NCGC00015883-02
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R-64,766
R-64-766
R-64766
R64,766
R64766
Rispen
Risperdal
Risperdal (TN)
Risperdal Consta
Risperdal M-Tab
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
SMR000466323
SPBio_003078
STK646402
Sequinan
Spiron
TL8000230
UNII-L6UH7ZF8HC
risperdone
risperidone
4
SerotoninPhase 4362750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
5Serotonin AgentsPhase 43156
6Serotonin AntagonistsPhase 41409
7Antipsychotic AgentsPhase 42401
8Tranquilizing AgentsPhase 44265
9Neurotransmitter Uptake InhibitorsPhase 43521
10Psychotropic DrugsPhase 46430
11Dopamine AgentsPhase 43836
12Central Nervous System DepressantsPhase 413403
13Dopamine AntagonistsPhase 41093
14Central Nervous System StimulantsPhase 42211
15Dopamine Uptake InhibitorsPhase 41331
16Neurotransmitter AgentsPhase 418340
17
Vitamin Eapproved, nutraceutical, vet_approvedPhase 2, Phase 341459-02-914985
Synonyms:
(+)-a-Tocopherol
(+)-alpha-Tocopherol
(+)-α-tocopherol
(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL
(2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
(2R,4'R,8'R)-a-Tocopherol
(2R,4'R,8'R)-alpha-Tocopherol
(2R,4'R,8'R)-α-tocopherol
(R,R,R)-a-Tocopherol
(R,R,R)-alpha-Tocopherol
(R,R,R)-α-tocopherol
5,7,8-Trimethyltocol
5,7,8-trimethyltocol
Amino-Opti-E
Aquasol E
D-alpha-Tocopherol
Daltose
Denamone
E-200 I.U. Softgels
 
E-Complex-600
E-Ferol
E-Vitamin succinate
Eprolin
Gordo-Vite E
Phytogermin
Phytogermine
RRR-alpha-tocopherol
RRR-alpha-tocopheryl
Tocopherol
Vitamin E
Vitamin Ea
Vitamin Plus E Softgells
Vitec
a-D-Tocopherol
a-Tocopherol
alpha-Tocopherol
alpha-delta-Tocopherol
alpha-tocopherol
d-α-tocopherol
delta-alpha-Tocopherol
18VitaminsPhase 2, Phase 35282
19TocopherolsPhase 2, Phase 3414
20TocotrienolsPhase 2, Phase 3410
21Calcium, DietaryPhase 3, Phase 2, Phase 15713
22TocotrienolNutraceuticalPhase 2, Phase 3410
23TocopherolNutraceuticalPhase 2, Phase 3414
24Omega 3 Fatty AcidNutraceuticalPhase 2, Phase 31018
25
MelphalanapprovedPhase 2729148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
 
Levofalan
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
26
alemtuzumabapproved, investigationalPhase 2310216503-57-0
Synonyms:
Campath
 
MabCampath
alemtuzumab
27
ThiotepaapprovedPhase 222652-24-45453
Synonyms:
 
Thioplex
28
FludarabineapprovedPhase 2115421679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ARAA
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-fluoro ARA-A
21679-14-1
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
Fludara, Fludarabine
 
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
29
AcetaminophenapprovedPhase 1, Phase 21026103-90-21983
Synonyms:
4'-Hydroxyacetanilide
4'-hydroxyacetanilide
4-(Acetylamino)phenol
4-Acetamidophenol
4-Acetaminophenol
4-Hydroxyacetanilide
4-Hydroxyanilid kyseliny octove
4-acetamidophenol
A-Per
A.F. Anacin
AC1Q1KYJ
AC1Q1KYK
APAP
Abenol
Abensanil
Abrol
Abrolet
Acamol
Accu-Tap
Acenol
Acephen
Acertol
Aceta Elixir
Aceta Tablets
Acetaco
Acetagesic
Acetalgin
Acetaminofen
Acetaminophen
Acetaminophen Uniserts
Acetamol
Acetavance
Acetofen
Actamin
Actamin Extra
Actamin Super
Actifed Plus
Actimol
Actimol Chewable Tablets
Actimol Children'S Suspension
Actimol Infants' Suspension
Actimol Junior Strength Caplets
Actron
Afebrin
Afebryl
Aferadol
Algesidal
Algina
Algomol
Algotropyl
Allay
Alpiny
Alpinyl
Alvedon
Amadil
Aminofen
Aminofen Max
Anacin
Anacin 3
Anacin-3
Anacin-3 Extra Strength
Anadin dla dzieci
Anaflon
Analter
Anapap
Andox
Anelix
Anexsia
Anexsia 10/660
Anexsia 5/325
Anexsia 7.5/325
Anexsia 7.5/650
Anhiba
Anoquan
Anti-Algos
Antidol
Anuphen
Apacet
Apacet Capsules
Apacet Elixir
Apacet Extra Strength Caplets
Apacet Extra Strength Tablets
Apacet Regular Strength Tablets
Apadon
Apamid
Apamide
Apitrelal
Apo-Acetaminophen
Arfen
Arthralgen
Asetam
Asomal
Aspac
Aspirin Free Anacin Maximum Strength Caplets
Aspirin Free Anacin Maximum Strength Gel Caplets
Aspirin Free Anacin Maximum Strength Tablets
Aspirin-Free Anacin
Aspirin-Free Excedrin Caplets
Asplin
Atasol
Atasol Caplets
Atasol Drops
Atasol Forte Caplets
Atasol Forte Tablets
Atasol Oral Solution
Atasol Tablets
Atralidon
Babikan
Bacetamol
Bancap
Bancap Hc
Banesin
Bayer Select
Bayer Select Allergy-Sinus
Bayer Select Head Cold
Bayer Select Headache Pain
Bayer Select Maximum Strength Headache Pain Relief Formula
Bayer Select Menstrual Multi-Symptom
Bayer Select Sinus Pain Relief
Ben-u-ron
Benmyo
Bickie-mol
Biocetamol
Bucet
Butalbital
Butapap
CCRIS 3
CHEBI:46195
Cadafen
Calapol
Calmanticold
Calonal
Calpol
Capital
Capital with Codeine
Captin
Causalon
Cefalex
Cetadol
Children'S Acetaminophen Elixir Drops
Children'S Acetaminophen Oral Solution
Children'S Tylenol Chewable
Claradol Codeine
Clixodyne
Co-Gesic
Cod-Acamol Forte
Codabrol
Codalgin
Codapane
Codicet
Codisal
Codisal Forte
Codoliprane
Codral Pain Relief
Cofamol
Conacetol
Contac Cough & Sore Throat Formula
Contra-Schmerz P
Coricidin
Coricidin D
Coricidin Sinus
Cosutone
Croix Blanche
Cuponol
Curadon
Curpol
Custodial
D oliprane
Dafalgan
Dapa
Dapa X-S
Darocet
Darvocet
Darvocet-N 50
Datril
Datril Extra-Strength
Daygrip
Demilets
Deminofen
Democyl
Demogripal
Desfebre
Dhamol
Dhc Plus
Dial-a-gesic
Dial-alpha-gesic
Dimindol
Dirox
Disprol
Dol-Stop
Dolcor
Dolefin
Dolegrippin
Dolene AP-65
Dolene Ap-65
Dolgesic
Doliprane
Dolko
Dolofugin
Doloreduct
Dolorfug
Dolorol Forte
Dolorstop
Dolotec
Dolprone
Dorocoff
Dresan
Dristan Cold No Drowsiness
Dristancito
Drixoral Plus
Duaneo
Dularin
Duorol
Duracetamol
Duradyne Dhc
Durapan
Dymadon
Dymadon Co
Dymadon Forte
Dypap
Ecosetol
Elixodyne
Empracet
Endecon
Enelfa
Eneril
Esgic
Esgic-Plus
Eu-Med
Excedrin
Excedrin Caplets
Excedrin Extra Strength Caplets
Excipain
Exdol
Exdol Strong
Fanalgic
Farmadol
Febranine
Febrectal
Febrectol
Febrex
Febricet
Febridol
Febrilix
Febrin
Febrinol
Febro-Gesic
Febrolin
Femcet
Fendon
Fensum
Fepanil
Fever All
Feverall
Feverall Junior Strength
Feverall Sprinkle Caps Junior Strength
Fevor
Finimal
Finiweh
Fioricet
Fluparmol
Fortalidon P
Freka-cetamol
Gattaphen T
Gelocatil
Geluprane
Genapap
Genapap Children'S Elixir
Genapap Children'S Tablets
Genapap Extra Strength Caplets
Genapap Extra Strength Tablets
Genapap Regular Strength Tablets
Genebs
Genebs Extra Strength Caplets
Genebs Regular Strength Tablets
Genebs X-Tra
Geralgine-P
Gripin Bebe
Grippostad
Gynospasmine
Hedex
Helon N
Homoolan
Hy-Phen
Hycomine Compound
Hydrocet
Ildamol
Inalgex
Infadrops
Infants' Feverall
Influbene N
Injectapap
Intensin
Janupap
Jin Gang
Junior Disprol
KBio1_000660
Kataprin
Kinder Finimal
Korum
Kratofin simplex
L024125
Labamol
Lekadol
Lemgrip
Lemsip
Lestemp
Liqiprine
Liquagesic
Liquigesic Co
Liquiprin
Liquiprin Children'S Elixir
Liquiprin Infants" Drops
Lonarid
Lonarid Mono
Lorcet-Hd
Lortab
Lupocet
Lyteca
Lyteca Syrup
Magnidol
Malex N
Malgis
Malidens
Maxadol
Medigesic Plus
Medinol Paediatric
Medocodene
Melabon Infantil
Mexalen
Midol Maximum Strength
Midol PM Night Time Formula
Midol Regular Strength
Midol Teen Formula
Migraleve Yellow
Minafen
Minoset
Miralgin
Momentum
Mono Praecimed
 
Multin
N-(4-Hydroxyphenyl)acetamide
N-Acetyl-4-aminophenol
N-Acetyl-p-aminophenol
N-acetyl-p-aminophenol
NAPA
NCX 701
NEBS
NSC3991
Naldegesic
Napafen
Napap
Naprinol
Nealgyl
Nebs
Neo-Fepramol
NeoCitran
Neodol
Neodolito
Neopap
Neotrend
Neuridon
New Cortal for Children
NilnOcen
Nina
No-Febril
Nobedon
Nodolex
Noral
Norcet
Norco
O-Acetaminophenol
Ofirmev
Oltyl
Oralgan
Oraphen-PD
Ortensan
Oxycet
Oxycocet
Oxycodone 2.5/Apap 500
Oxycodone 5/Apap 500
PCM Paracetamol Lichtenstein
Paceco
Pacemo
Pacemol
Pacet
Pacimol
Paedialgon
Paedol
Painex
Paldesic
Pamol
Panacete
Panadeine
Panadeine Co
Panadiene
Panado-Co
Panado-Co Caplets
Panadol
Panadol Extra Strength
Panadol Junior Strength Caplets
Panadol Maximum Strength Caplets
Panadol Maximum Strength Tablets
Panale ve
Panaleve
Panamax
Panasorb
Panasorbe
Panets
Panex
Panodil
Panofen
Pantalgin
Papa-Deine
Papa-Deine #3
Papa-Deine #4
Para-Suppo
Para-Tabs
Paracemol
Paracenol
Paracet
Paracetamol
Paracetamol AL
Paracetamol Antipanin P
Paracetamol BC
Paracetamol Basics
Paracetamol DC
Paracetamol Dr. Schmidgall
Paracetamol Fecofar
Paracetamol Genericon
Paracetamol Hanseler
Paracetamol Harkley
Paracetamol Heumann
Paracetamol Hexal
Paracetamol Italfarmaco
Paracetamol Nycomed
Paracetamol PB
Paracetamol Raffo
Paracetamol Ratiopharm
Paracetamol Rosch
Paracetamol Saar
Paracetamol SmithKline Beecham
Paracetamol Stada
Paracetamol Winthrop
Paracetamol von ct
Paracetamole
Paracetamolo
Paracetamolum
Paracetanol
Paracetol
Paracin
Paracod
Paracodol
Paracétamol
Parador
Paradrops
Parakapton
Parake
Paralen
Paralief
Paralink
Paralyoc
Paramol
Paramolan
Paranox
Parapan
Parasedol
Parasin
Paraspen
Parcetol
Parelan
Parmol
Parogal
Paroma
Pasolind
Pasolind N
Pe-Tam
Pediapirin
Pediatrix
Pedric
Percocet
Percocet-5
Percocet-Demi
Percogesic with Codeine
Perdolan Mono
Perfalgan
Phenaphen
Phenaphen Caplets
Phenaphen W/Codeine
Phendon
Phenipirin
Phogoglandin
Phrenilin
Phrenilin Forte
Pinex
Piramin
Pirinasol
Plicet
Polmofen
Predimol
Predualito
Prestwick_13
Prodol
Prompt
Prontina
Propacet
Propacet 100
Proval #3
Puernol
Pulmofen
Pyregesic-C
Pyrigesic
Pyrinazine
Pyromed
Quiet World
Redutemp
Reliv
Remedol
Rhinex D-Lay Tablets
Rivalgyl
Robigesic
Robitussin Night Relief
Rockamol Plus
Rounox
Roxicet
Roxicet 5/500
Roxilox
RubieMol
Rubophen
Rupemol
SK-Apap
SPBio_002836
Salzone
Sanicet
Sanicopyrine
Scanol
Scentalgyl
Scherzatabletten Rezeptur 534
Schmerzex
Sedalito
Sedapap
Semolacin
Servigesic
Seskamol
Setakop
Setamol
Setol
Sifenol
Sinaspril
Sine-Off Sinus Medicine Caplets
Sinedol
Sinmol
Sinubid
Snaplets-FR
Spalt N
Spalt fur die nacht
St Joseph Aspirin-Free
St Joseph Aspirin-Free for Children
St. Joseph Cold Tablets for Children
St. Joseph Fever Reducer
Stanback
Stopain
Sudafed Severe Cold Formula
Sudafed Sinus
Sunetheton
Supac
Supadol mono
Supofen
Suppap
Suppap-120
Suppap-325
Suppap-650
Supramol-M
Synalgos-Dc-A
TYL
Tabalgin
Tachiprina
Talacen
Tapanol
Tapanol Extra Strength Caplets
Tapanol Extra Strength Tablets
Tapar
Tavist Allergy/Sinus/Headache
Tazamol
Temlo
Tempanal
Tempra
Tempra Caplets
Tempra Chewable Tablets
Tempra D.S
Tempra Drops
Tempra Syrup
Tencon
Termacet
Termalgin
Termalgine
Termofren
TheraFlu
Tibinide
Tibizide
Tiffy
Tisin
Tisiodrazida
Titralgan
Tizide
Tocris-1706
Toximer P
Tralgon
Treupel N
Treupel mon
Treuphadol
Triad
Triaminic Sore Throat Formula
Triaprin
Tricoton
Tussapap
Ty lenol
Tycolet
Tylenol
Tylenol (TN)
Tylenol Allergy Sinus
Tylenol Arthritis Extended Relief
Tylenol Caplets
Tylenol Children'S Chewable Tablets
Tylenol Children'S Elixir
Tylenol Children'S Suspension Liquid
Tylenol Drops
Tylenol Elixir
Tylenol Extra Strength Adult Liquid Pain Reliever
Tylenol Extra Strength Caplets
Tylenol Extra Strength Gelcaps
Tylenol Extra Strength Tablets
Tylenol Gelcaps
Tylenol Infants Drops
Tylenol Infants" Suspension Drops
Tylenol Junior Strength Caplets
Tylenol Junior Strength Chewable Tablets
Tylenol Regular Strength Caplets
Tylenol Regular Strength Tablets
Tylenol Tablets
Tylex
Tylex CD
Tylol
Tylox
Tylox-325
Tymol
Ultracet
Upsanol
Utragin
Valadol
Valgesic
Valorin
Valorin Extra
Vanquish
Veralgina
Vermidon
Verpol
Viclor Richet
Vicodin
Vicodin Es
Vicodin Hp
Vips
Viruflu
Vivimed
Volpan
Wygesic
Zatinol
Zolben
acetaminofén
acétaminophène
alpha-Per
p-(Acetylamino)phenol
p-Acetamidophenol
p-Acetaminophenol
p-Acetylaminophenol
p-Hydroxyacetanilide
p-Hydroxyphenolacetamide
p-acetamidophenol
p-acetaminophenol
p-hydroxy-acetanilid
p-hydroxyacetanilide
p-hydroxyphenolacetamide
30
Cyclosporineapproved, investigational, vet_approvedPhase 1, Phase 292279217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
31
Prednisoloneapproved, vet_approvedPhase 1, Phase 2119350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
32
Daclizumabapproved, investigationalPhase 1, Phase 298152923-56-3
Synonyms:
 
Dacliximab
Daclizumab beta
33
VidarabineapprovedPhase 252124356-66-932326, 21704
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9-Arabinosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
ADENOSINE, U.S.P.
ADN
AI3-52413
AI3-52821
AR-1H6029
ARA-A NSC 247519
Ade-Rib
Adenine Arabinoside
Adenine arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
Adenosine-8-14C
Adensoine
Ambap5536-17-4
Ara A
Ara-A
Ara-ATP
Araadenosine
Arabinoside Adenine
Arabinoside adenine
Arabinosyl Adenine
Arabinosyl adenine
Arabinosyl-adenine
Arabinosyladenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
Bio1_000437
Bio1_000926
Bio1_001415
Boniton
C00212
CAS-5536-17-4
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
Caswell No. 010B
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
 
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
LS-15059
LS-15085
Lopac0_000123
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC-404241
NSC247519
NSC404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
PDSP1_001036
PDSP2_001020
Pallacor
Polyadenosine
Polyriboadenosine
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
Prestwick_983
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
SPECTRUM1500107
SPECTRUM1500609
SR 96225
SR-96225
STK361815
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spectrum_001894
Spongoadenosine
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
VIRDARABINE
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira ATM
Vira-A
Vira-A, Vidarabine
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
adenine-D-ribose
adenosine
alpha-Ara A
beta-Adenosine
beta-Ara A
beta-D-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
34
Mycophenolic acidapprovedPhase 1, Phase 295224280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
35
Miconazoleapproved, investigational, vet_approvedPhase 1, Phase 2370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
36
Tacrolimusapproved, investigationalPhase 1, Phase 21102104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
37
Mycophenolate mofetilapproved, investigationalPhase 1, Phase 2952128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
38
Methylprednisoloneapproved, vet_approvedPhase 1, Phase 2119383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
39HormonesPhase 1, Phase 214415
40Antineoplastic Agents, AlkylatingPhase 24603
41AntimetabolitesPhase 212054
42Immunosuppressive AgentsPhase 2, Phase 113086
43Alkylating AgentsPhase 24827
44Antimetabolites, AntineoplasticPhase 27361
45Vidarabine PhosphatePhase 2127
46Methylprednisolone HemisuccinatePhase 1, Phase 21193
47Methylprednisolone acetatePhase 1, Phase 21193
48ImmunoglobulinsPhase 26394
49Neuroprotective AgentsPhase 1, Phase 21716
50Prednisolone phosphatePhase 1, Phase 21193

Interventional clinical trials:

(show all 33)
idNameStatusNCT IDPhase
1The Psychiatric and Cognitive Phenotypes in Velocardiofacial SyndromeRecruitingNCT00768820Phase 4
2Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.Unknown statusNCT02070211Phase 2, Phase 3
3Effects of PTH Replacement on Bone in HypoparathyroidismActive, not recruitingNCT00395538Phase 3
4Immune Disorder HSCT ProtocolRecruitingNCT01821781Phase 2
5Thymus Transplantation in DiGeorge Syndrome #668Active, not recruitingNCT00576407Phase 2
6Thymus Transplantation Dose in DiGeorge #932Active, not recruitingNCT00576836Phase 2
7Phase I/II Thymus Transplantation With Immunosuppression #950Active, not recruitingNCT00579527Phase 1, Phase 2
8Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited DisordersActive, not recruitingNCT00553098Phase 2
9Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial SyndromeTerminatedNCT01127503Phase 2
10Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric ConditionsCompletedNCT02895906Phase 1
11Parathyroid and Thymus Transplantation in DiGeorge #931Active, not recruitingNCT00566488Phase 1
12Thymus Transplantation With ImmunosuppressionActive, not recruitingNCT00579709Phase 1
13Serum-Free Thymus Transplantation in DiGeorge AnomalyTerminatedNCT00849888Phase 1
14Genetics and Psychopathology in the 22q11 Deletion SyndromeUnknown statusNCT00161109
15Genetic Modifiers for 22q11.2 SyndromeUnknown statusNCT00916955
16Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial SyndromeUnknown statusNCT00005102
17Cognitive Remediation in 22q11DSCompletedNCT01781923
18Resolution of Primary Immune Defect in 22q11.2 Deletion SyndromeCompletedNCT02460328
19Computerized Cognitive Skills Training for Adolescents With Velocardiofacial SyndromeCompletedNCT00917189
20Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion SyndromesCompletedNCT00004351
21Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome StudyCompletedNCT00105274
22Middle and Inner Ear Malformation in Children With Velocardiofacial SyndromeCompletedNCT00784173
23Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac DefectsCompletedNCT00004361
24Microarray Analysis in Syndromic ObesityCompletedNCT01043198
25SNP-based Microdeletion and Aneuploidy RegisTry (SMART)RecruitingNCT02381457
26Non-Invasive Chromosomal Evaluation of 22q11.2RecruitingNCT02541058
27Expanded Noninvasive Genomic Medical Assessment: The Enigma StudyRecruitingNCT02787486
28Whole Blood Specimen Collection From Pregnant SubjectsRecruitingNCT02430584
29Perception of Facial Emotions in Schizophrenia and 22q11 Deletion SyndromeActive, not recruitingNCT02634671
30Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion SyndromeActive, not recruitingNCT00556530
31Thymus Transplantation Safety-EfficacyAvailableNCT01220531
32Prenatal Examination of Deletion 22q11 Syndrome : Thymic Dysgenesis THYMI StudyEnrolling by invitationNCT02890472
33Infection in DiGeorge Following CHD SurgeryTerminatedNCT00278005

Search NIH Clinical Center for Velocardiofacial Syndrome

Genetic Tests for Velocardiofacial Syndrome

About this section

Genetic tests related to Velocardiofacial Syndrome:

id Genetic test Affiliating Genes
1 Shprintzen Syndrome27
2 22q11.2 Deletion Syndrome24 TBX1
3 Sedlackova Syndrome24
4 Velocardiofacial Syndrome24

Anatomical Context for Velocardiofacial Syndrome

About this section

MalaCards organs/tissues related to Velocardiofacial Syndrome:

36
Heart, Thymus, Kidney, T cells, Lung, Brain, Tonsil

Publications for Velocardiofacial Syndrome

About this section

Articles related to Velocardiofacial Syndrome:

(show top 50)    (show all 207)
idTitleAuthorsYear
1
An exploratory study of predisposing genetic factors for DiGeorge/velocardiofacial syndrome. (28059126)
2017
2
Longitudinal study of premorbid adjustment in 22q11.2 deletion (velocardiofacial) syndrome and association with psychosis. (26864886)
2016
3
Variability in Clinical and Anatomical Manifestation of Velocardiofacial Syndrome Presents Diagnostic and Policy Uncertainty. (27732116)
2016
4
Velocardiofacial syndrome in Mexican patients: Unusually high prevalence of congenital heart disease. (26409294)
2015
5
Evaluation of the levator veli palatini muscle thickness in patients with velocardiofacial syndrome using magnetic resonance imaging. (26031215)
2015
6
Characteristic face: a key indicator for direct diagnosis of 22q11.2 deletions in Chinese velocardiofacial syndrome patients. (23342150)
2013
7
Gyrification differences in children and adolescents with velocardiofacial syndrome and attention-deficit/hyperactivity disorder: A pilot study. (24377834)
2013
8
Internal carotid artery variations in velocardiofacial syndrome patients and its implications for surgery. (23969952)
2013
9
Extensive pneumatization of the ethmoid sinus in a case of velocardiofacial syndrome. (24366697)
2013
10
Understanding velocardiofacial syndrome: how recent discoveries can help you improve your patient outcomes. (23000736)
2012
11
An algorithm for application of furlow palatoplasty to the treatment of velocardiofacial syndrome-associated velopharyngeal insufficiency. (21451369)
2011
12
Discussion. Speech outcomes following pharyngeal flap in patients with velocardiofacial syndrome. (21532432)
2011
13
Neuroanatomic predictors to prodromal psychosis in velocardiofacial syndrome (22q11.2 deletion syndrome): a longitudinal study. (21195387)
2011
14
Speech outcomes and velopharyngeal function after surgical treatment of velopharyngeal insufficiency in individuals with signs of velocardiofacial syndrome. (21959422)
2011
15
Velopharyngeal valving during speech, in patients with velocardiofacial syndrome and patients with non-syndromic palatal clefts after surgical and speech pathology management. (21820188)
2011
16
Dental development and tooth agenesis in children with velocardiofacial syndrome. (21689177)
2011
17
Speech outcomes following pharyngeal flap in patients with velocardiofacial syndrome. (21532431)
2011
18
The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. (22149470)
2011
19
The role of cephalometry in assessing velopharyngeal dysfunction in velocardiofacial syndrome. (21305558)
2011
20
A prospective study of influenza vaccination and a comparison of immunologic parameters in children and adults with chromosome 22q11.2 deletion syndrome (digeorge syndrome/velocardiofacial syndrome). (21863400)
2011
21
Cognitive phenotype of velocardiofacial syndrome: a review. (21764255)
2011
22
Failure of neuraxial anaesthesia in a patient with Velocardiofacial syndrome. (21602040)
2011
23
Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). (21200182)
2011
24
Clinical utility gene card for: DiGeorge syndrome, velocardiofacial syndrome, Shprintzen syndrome, chromosome 22q11.2 deletion syndrome (22q11.2, TBX1). (20125192)
2010
25
Craniofacial morphology in patients with velocardiofacial syndrome. (20426673)
2010
26
Velocardiofacial syndrome presenting as chronic mania. (21105957)
2010
27
Quality of life among children with velocardiofacial syndrome. (20426676)
2010
28
Secondary immunologic consequences in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). (20472505)
2010
29
The morphology of the sella turcica in velocardiofacial syndrome suggests involvement of a neural crest developmental field. (20503320)
2010
30
Psychosis in children with velocardiofacial syndrome (22q11.2 deletion syndrome). (19302762)
2009
31
Sequential treatment of speech disorders in velocardiofacial syndrome patients: an 8-year retrospective evaluation. (19816377)
2009
32
BAC array CGH in patients with Velocardiofacial syndrome-like features reveals genomic aberrations on chromosome region 1q21.1. (20030804)
2009
33
Insights into brain development from neurogenetic syndromes: evidence from fragile X syndrome, Williams syndrome, Turner syndrome and velocardiofacial syndrome. (19376197)
2009
34
Juvenile myoclonic epilepsy with photosensitivity in a female with Velocardiofacial syndrome (del(22)(q11.2))--causal relationship or coincidence? (19695908)
2009
35
Stranded, part II: Velocardiofacial syndrome, behavioral neurogenetics, and the study of developmental psychopathology. (19855217)
2009
36
Structural and functional causes of hypernasality in velocardiofacial syndrome. A pilot study. (19299897)
2009
37
Utilization of three-dimensional computed tomography for craniofacial phenotypic analysis in children with velocardiofacial syndrome. (19881378)
2009
38
Surgical planning for restoring velopharyngeal function in velocardiofacial syndrome. (19720406)
2009
39
Meta-analysis of magnetic resonance imaging studies in chromosome 22q11.2 deletion syndrome (velocardiofacial syndrome). (19819113)
2009
40
Hypocalcaemia as presenting symptom of velocardiofacial syndrome. (19307682)
2009
41
Clicks produced as compensatory articulations in two adolescents with velocardiofacial syndrome. (18616363)
2008
42
Outcome of velopharyngoplasty in patients with velocardiofacial syndrome. (19015444)
2008
43
Tooth abnormalities and soft tissue changes in patients with velocardiofacial syndrome. (18554940)
2008
44
Videomanometric evaluation of pharyngo-oesophageal dysmotility in children with velocardiofacial syndrome. (18162840)
2008
45
22q11.2 distal deletion: a recurrent genomic disorder distinct from DiGeorge syndrome and velocardiofacial syndrome. (18179902)
2008
46
Through-and-through dissection of the soft palate for high pharyngeal flap inset: a new technique for the treatment of velopharyngeal incompetence in velocardiofacial syndrome. (18766049)
2008
47
Associations between performance on the Rey-Osterrieth Complex Figure and regional brain volumes in children with and without velocardiofacial syndrome. (18788013)
2008
48
Chromosome 22q11.2 deletion syndrome: DiGeorge syndrome/velocardiofacial Syndrome. (18424337)
2008
49
Congenital absence of the nasolacrimal duct in velocardiofacial syndrome. (18314073)
2008
50
Factors affecting articulation skills in children with velocardiofacial syndrome and children with cleft palate or velopharyngeal dysfunction: a preliminary report. (18333642)
2008

Variations for Velocardiofacial Syndrome

About this section

UniProtKB/Swiss-Prot genetic disease variations for Velocardiofacial Syndrome:

70
id Symbol AA change Variation ID SNP ID
1TBX1p.Phe148TyrVAR_035025rs28939675
2TBX1p.His194GlnVAR_035026rs74315522

Clinvar genetic disease variations for Velocardiofacial Syndrome:

5
id Gene Variation Type Significance SNP ID Assembly Location
1TBX1TBX1, 23-BP DEL, NT1320deletionPathogenic
2TBX1NM_ 080647.1(TBX1): c.582C> G (p.His194Gln)SNVPathogenicrs74315522GRCh37Chr 22, 19751747: 19751747

Copy number variations for Velocardiofacial Syndrome from CNVD:

6 (show top 50)    (show all 67)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1173831142600000147000000DeletionVelocardiofacial syndrome
239937101220000017300000DeletionVelocardiofacial syndrome
38148714103000000106368585Deletion22q11 deletion syndrome
491520153120000033600000DeletionVelocardiofacial syndrome
5157439211630000024300000Deletion22q11.2 microdeletion syndrome
616019122149691432MicrodeletionCOMTVelocardiofacial syndrome
716019222149691432MicrodeletionPRODHVelocardiofacial syndrome
816019322149691432MicrodeletionTBX1Velocardiofacial syndrome
916019422149691432MicrodeletionZDHHC8Velocardiofacial syndrome
10160212221180000024300000Deletion22q11 deletion syndrome
11160213221180000024300000Deletion22q11 deletion syndrome
12160214221180000024300000Deletion22q11 deletion syndrome
13160226221180000024300000DeletionShprintzen syndrome
14160232221180000024300000DeletionCF79846622q11 deletion syndrome
15160234221180000024300000DeletionCOMT22q11 deletion syndrome
16160238221180000024300000DeletionCOMTvelo-cardio-facial syndrome
17160239221180000024300000DeletionD22S93622q11 deletion syndrome
18160243221180000024300000DeletionDGCR6velo-cardio-facial syndrome
19160246221180000024300000DeletionHIC222q11 deletion syndrome
20160247221180000024300000DeletionPRODH22q11 deletion syndrome
21160251221180000024300000DeletionPRODHvelo-cardio-facial syndrome
22160252221180000024300000DeletionSLC7A422q11 deletion syndrome
23160253221180000024300000DeletionTBX122q11 deletion syndrome
24160256221180000024300000DeletionUSP1822q11 deletion syndrome
25160261221180000024300000Microdeletion22q11.2 microdeletion syndrome
26160267221180000024300000MicrodeletionShprintzen syndrome
27160269221180000024300000MicrodeletionVelocardiofacial syndrome
28160270221180000024300000MicrodeletionVelocardiofacial syndrome
29160280221180000024300000Microdeletions22q11 deletion syndrome
30160281221180000024300000Microdeletions22q11.2 microdeletion syndrome
31160321221443327318691904Deletion22q11 deletion syndrome
32160775221630000024300000Deletion22q11.2 microdeletion syndrome
33160776221630000024300000Deletion22q11.2 microdeletion syndrome
34160777221630000024300000Deletion22q11.2 microdeletion syndrome
35160778221630000024300000Deletion22q11.2 microdeletion syndrome
36160779221630000024300000Deletion22q11.2 microdeletion syndrome
37160780221630000024300000Deletion22q11.2 microdeletion syndrome
38160781221630000024300000Deletion22q11.2 microdeletion syndrome
39160799221630000024300000DeletionVelocardiofacial syndrome
40160800221630000024300000DeletionVelocardiofacial syndrome
41160801221630000024300000DeletionVelocardiofacial syndrome
42160803221630000024300000Deletionvelo-cardio-facial syndrome
43160804221630000024300000Deletionvelo-cardio-facial syndrome
44160805221630000024300000DeletionCHEK222q11.2 microdeletion syndrome
45160811221630000024300000DeletionTBX122q11.2 microdeletion syndrome
46160816221630000024300000DeletionTbx122q11.2 microdeletion syndrome
47160827221630000024300000Microdeletion22q11.2 microdeletion syndrome
48160828221630000024300000Microdeletion22q11.2 microdeletion syndrome
49160829221630000024300000Microdeletion22q11.2 microdeletion syndrome
50160830221630000024300000Microdeletion22q11.2 microdeletion syndrome

Expression for genes affiliated with Velocardiofacial Syndrome

About this section
Search GEO for disease gene expression data for Velocardiofacial Syndrome.

Pathways for genes affiliated with Velocardiofacial Syndrome

About this section

GO Terms for genes affiliated with Velocardiofacial Syndrome

About this section

Biological processes related to Velocardiofacial Syndrome according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1face morphogenesisGO:006032510.8CLDN5, TBX1
2blood coagulation, intrinsic pathwayGO:000759710.7GP1BA, GP1BB, GP9
3anatomical structure morphogenesisGO:000965310.7GSC2, HIRA, MRPL40
4blood coagulationGO:000759610.6GP1BA, GP1BB, GP9, JMJD1C
5hemostasisGO:000759910.6GP1BA, GP1BB, GP9
6cell adhesionGO:000715510.3ARVCF, DGCR2, DGCR6, GP1BA, GP1BB, GP9
7platelet activationGO:003016810.0GP1BA, GP1BB, GP9

Sources for Velocardiofacial Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet